<DOC>
	<DOC>NCT00144859</DOC>
	<brief_summary>This is a 28-day, placebo controlled clinical study assessing the safety, tolerability anti-inflammatory effect and pharmacokinetics of SB681323 in patients with COPD (Chronic Obstructive Pulmonary Disease).</brief_summary>
	<brief_title>Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Inclusion criteria: Nonchildbearing potential. Clinical diagnosis of COPD. Cigarette smoking history of greater than or equal to 10 pack years. Postbronchodilator FEV1 to FVC ratio (FEV1:FVC) &lt; 0.7 Postbronchodilator FEV1 50% 80% of predicted normal. Receiving inhaled corticosteroids for a minimum of 6 weeks prior to Screening. Serum CRP concentration greater than 3mg/L. Exclusion criteria: Current diagnosis of asthma. Active tuberculosis, sarcoidosis or bronchiectasis. History of any type of malignancy, rheumatoid arthritis or other conditions associated with chronic inflammation. Clinically significant renal or hepatic disease. History of increased liver function tests, or patients receiving hormone replacement therapy, statins or systemic or topical corticosteroids.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>P38 map kinase</keyword>
	<keyword>CRP</keyword>
	<keyword>COPD</keyword>
	<keyword>safety</keyword>
</DOC>